Lincoln Pharmaceuticals' Q4 FY 2025-26 Quarterly Results

Result Summary

• Lincoln Pharmaceuticals Ltd reported a 0.9% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 13.5%.
• Its expenses for the quarter were up by 13.4% QoQ and 14.7% YoY.
• The net profit decreased 59.3% QoQ and increased 0.4% YoY.
• The earnings per share (EPS) of Lincoln Pharmaceuticals Ltd stood at 5.81 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Lincoln Pharmaceuticals Ltd is a prominent player in the pharmaceutical industry, known for its extensive range of pharmaceutical products and healthcare solutions. The company specializes in manufacturing and distributing a wide array of medicines, including generic formulations, over-the-counter products, and specialty pharmaceuticals. The company is committed to maintaining high standards of quality and efficacy in its products, catering to both domestic and international markets. While the specifics of any recent major developments are not available in the provided data, Lincoln Pharmaceuticals Ltd continues to focus on innovation and expansion within its sector.

Revenue

In the fourth quarter of fiscal year 2026, Lincoln Pharmaceuticals Ltd reported a total income of ₹183.08 crores. This represents a quarter-over-quarter increase of 0.9% from ₹181.47 crores recorded in the previous quarter (Q3FY26), and a year-over-year growth of 13.5% from ₹161.30 crores in the same quarter of the previous year (Q4FY25). The upward trajectory in total income highlights the company's ability to sustain its revenue growth over both quarterly and annual periods. Consistent revenue performance reflects the company's market presence and its capability to adapt to varying market conditions.

Profitability

The company's profitability metrics depict a varied performance over the analyzed periods. The profit before tax (PBT) for Q4FY26 was ₹16.70 crores, which marks a significant decrease of 51.9% on a quarter-over-quarter basis from ₹34.72 crores in Q3FY26. However, compared to the same quarter in the previous year, there was a slight increase of 2.8% from ₹16.25 crores in Q4FY25. The profit after tax (PAT) in Q4FY26 was ₹11.63 crores, a substantial decline of 59.3% from the previous quarter's ₹28.60 crores, while it showed a marginal year-over-year rise of 0.4% compared to ₹11.58 crores in Q4FY25. These figures indicate a mixed performance in profitability on a year-over-year basis, even as the company faced challenges quarter-over-quarter.

Operating Metrics

The company's total expenses in Q4FY26 were reported at ₹166.37 crores, reflecting a 13.4% increase from ₹146.75 crores in Q3FY26, and a 14.7% rise from ₹145.06 crores in Q4FY25. This upward trend in expenses suggests an increase in operational costs. The tax expense for Q4FY26 was ₹5.07 crores, down 17.2% from ₹6.12 crores in Q3FY26, but up 8.6% from ₹4.67 crores in Q4FY25. Earnings per share (EPS) in Q4FY26 stood at ₹5.81, a decrease of 59.3% from ₹14.28 in Q3FY26, and a slight increase of 0.5% from ₹5.78 in Q4FY25. These operating metrics provide insight into the company's cost structure and its impact on overall financial performance.